Introduction {#s1}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a serious threat to global public health.[@b1]^,^[@b2] Although the virus appears to be only partially similar to severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, all of these viral infections are responsible for severe and potentially lethal acute respiratory syndromes in humans.[@b3] Unfortunately, to date, there are no specific/targeted drugs, or vaccines, and the number of SARS-CoV-2-positive patients is growing in many parts of the world. The world and China map showing the geographical distribution of coronavirus disease 2019 (COVID-19) is shown in [Figure 1](#f01){ref-type="fig"}; the cut-off date for this data extraction was March 5, 2020.[@b4]

![Geographical distribution of COVID-19, using the cut-off date for data extraction of March 5, 2020.](JCTH-8-018-g001){#f01}

Surprisingly, in addition to the acute respiratory symptoms, patients with COVID-19 also have varying degrees of liver damage/dysfunction. For example, Chen *et al.*[@b5] showed that more than a third of COVID-19 patients have some liver function test abnormalities. Most of these infected patients had mild-to-moderate elevations of serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels; one patient had severely elevated serum aminotransferases (ALT of 7590 U/L, AST of 1445 U/L).[@b5] Since COVID-19-related liver dysfunction is now attracting widespread attention, this review discusses the epidemiological characteristics, the potential mechanisms, and the treatment options for liver dysfunction induced by COVID-19.

Epidemiological characteristics of COVID-19-related liver dysfunction {#s2}
=====================================================================

To better understand the distribution of COVID-19-related liver dysfunction in different regions of the world, we searched the available literature between December 11, 2019 and February 20, 2020. The literature search focused on initial case reports and case series covering COVID-19 patients, with a clear description of liver function tests and results. All case reports without any data on patients' liver function tests were excluded. Finally, we included 14 eligible studies, including 5 case reports ([Table 1](#t01){ref-type="table"}) and 9 case series ([Table 2](#t02){ref-type="table"}).[@b5]^--^[@b18] By reviewing these 14 studies, we have described geographical and demographic characteristics of COVID-19-related liver dysfunction (as summarized below).

###### Demographic and liver function characteristics of patients with COVID-19 based on the first case reports in three countries

  Author, Year                 Country            Age (years)   Sex      AST (IU/L)                                   ALT (IU/L)                                    COVID-19 Disease severity   Prior history of liver diseases   Drugs                                           
  ---------------------------- ------------------ ------------- -------- -------------------------------------------- --------------------------------------------- --------------------------- --------------------------------- ----------------------------------- ----------- ----
  Zhang YH, 2020[@b6]          China (Haikou)     3 months      Female   Normal                                       Normal                                        Non-severe                  No                                Azithromycin, Ceftazidime           Paramivir   NA
  Chen F, 2020[@b7]            China (Wuhan)      1             Male     Normal                                       Normal                                        Severe                      NA                                Meropenem, Linezolid, Oseltamivir   NA          NA
  Cai JH, 2020[@b8]            China (Shanghai)   7             Male     33                                           17                                            Non-severe                  No                                Levofloxacin                        NA          NA
  Holshue ML, 2020[@b9]        United States      35            Male     72 (16.4)[^\*^](#table1fn2){ref-type="fn"}   124 (30.3)[^\*^](#table1fn2){ref-type="fn"}   Non-severe                  No                                NA                                  NA          NA
  Silverstein WK, 2020[@b10]   Canada             56            Male     NA                                           29                                            Non-severe                  NA                                NA                                  NA          NA

AST: aspartate aminotransferase. ALT: alanine aminotransferase. Liver diseases: any liver disease that can cause serum liver enzyme changes, such as viral hepatitis, autoimmune hepatitis, etc. NA: not available. Normal ranges for AST and ALT: AST \< 40 IU/L and ALT \< 40 IU/L.

Standard deviation of liver enzyme fluctuations during hospitalization

###### Main characteristics related to liver disease in patients with COVID-19 infection in different Chinese regions based on a series of case reports

  Author, Year           Country                Sample size (n)   Abnormal AST (%)   AST (IU/L)         Abnormal ALT (%)   ALT (IU/L)          Male, n (%)   Age (years)                             Disease severity   History of liver diseases (%)   Drugs                                  
  ---------------------- ---------------------- ----------------- ------------------ ------------------ ------------------ ------------------- ------------- --------------------------------------- ------------------ ------------------------------- ----------- ------------- ------------ -----------
  Guan WJ 2020[@b11]     China (Multi-center)   1099              168 (22.2)         NA                 158 (21.3)         NA                  640 (58.2)    47.0 (35.0--58.0)                       173 (15.7)         926 (84.3)                      23 (2.1)    632 (57.5)    393 (35.8)   30 (2.7)
  Xu XW, 2020[@b12]      China (Zhejiang)       62                10 (16.1)          26 (20--32)        NA                 22 (14--34)         36 (58.1)     41.0 (32.0--52.0)                       NA                 NA                              7 (11.3)    28 (45.2)     55 (88.7)    NA
  Chen NS, 2020[@b5]     China (Wuhan)          99                35 (35.3)          34 (26--48)        28 (28.2)          39 (22--53)         67 (68.7)     55.5 ± 35.1                             NA                 NA                              11 (11.1)   70 (70.7)     75 (75.8)    15 (15.2)
  Chen L, 2020[@b13]     China (Wuhan)          29                7 (24.1)           NA                 5 (17.2)           NA                  21 (72.4)     56.0[^\*^](#table2fn2){ref-type="fn"}   14 (48.3)          15 (51.7)                       NA          NA            NA           NA
  Wang DW, 2020[@b14]    China (Wuhan)          138               NA                 31 (24--51)        NA                 24 (16--40)         75 (54.3)     56.0 (42.0--68.0)                       36 (26.1)          102 (73.9)                      4 (2.9)     89 (64.5)     124 (89.9)   NA
  Pan F, 2020[@b15]      China (Wuhan)          21                NA                 32 ± 20 (15--95)   NA                 42 ± 31 (12--107)   6 (28.6)      40.0 ± 9.0                              0 (0.0)            21 (100.0)                      NA          NA            NA           NA
  Liu C, 2020[@b16]      China (Multi-center)   32                2 (6.2)            25 (19--32)        9 (28.1)           26 (17--46)         20 (62.5)     38.5 (26.3--45.8)                       4 (12.5)           28 (87.5)                       1 (3.13)    NA            NA           NA
  *Huang C 2020[@b17]*   China (Wuhan)          41                15 (36.6)          34 (26--48)        NA                 32 (21--50)         30 (73.2)     49.0 (41.0--58.0)                       13 (31.7)          28 (68.3)                       1 (2.4)     41 (100.0%)   38 (92.7%)   NA
  Chen HJ 2020[@b18]     China (Wuhan)          9                 3 (33.3)           24 (21--119)       3 (33.3)           16 (11--58)         0 (0)         28 (26--34)                             0 (0.0)            9 (100.0)                       NA          9 (100.0%)    6 (66.7%)    NA

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; NA, not available. Liver diseases: any liver disease that can cause liver enzyme changes, such as viral hepatitis, autoimmune hepatitis, etc. Normal range for AST and ALT: AST \< 40 IU/L and ALT \< 40 IU/L.

Median, no interquartile range

Geographical distribution of COVID-19-related liver dysfunction {#s2-1}
---------------------------------------------------------------

In two Chinese multicenter surveys, one of which was led by the First Affiliated Hospital of Guangzhou Medical University, including 552 hospitals in 31 provinces/provincial municipalities through January 29th, 2020 and the other was led by the First Hospital of Lanzhou University including 7 hospitals, a considerable number of patients with COVID-19 had some abnormalities in liver function tests.[@b11]^,^[@b16] In particular, 6.2% to 22.2% of patients had increased serum AST levels ([Fig. 2](#f02){ref-type="fig"}) and 21.3% to 28.1% of patients had increased serum ALT levels, respectively.[@b11]^,^[@b16] Of the six studies performed in Wuhan, China,[@b5]^,^[@b13]^--^[@b15]^,^[@b17]^,^[@b18] only four included data on the proportion of patients with abnormal liver function test results. Specifically, in these four studies, the proportion of infected patients with increased serum AST levels ranged from 24.1% to 36.6% ([Fig. 2](#f02){ref-type="fig"}).[@b5]^,^[@b13]^,^[@b17]^,^[@b18] In a survey from Zhejiang Province, China, the proportion of patients with increased serum AST levels was only 16.1%, whereas the proportion of those with increased serum ALT levels was not specified.[@b12] It seems likely that the proportion of infected patients with increased serum AST levels in Wuhan (i.e. the area in which the epidemic of COVID-19 started) is much greater than cases reported outside Wuhan. It is plausible to speculate that there may have been a higher viral load of COVID-19 in exposed patients in Wuhan, where the infection began and was concentrated in a greater proportion of the population.

![Proportion of patients with liver dysfunction in Chinese regions: Wuhan and outside Wuhan.](JCTH-8-018-g002){#f02}

Sex distribution of COVID-19-related liver dysfunction {#s2-2}
------------------------------------------------------

A total of six case series reporting the percentage of abnormal liver function test results amongst COVID-19 patients suggested that the proportion of infected men with increased serum AST levels was higher than that observed in infected women.[@b5]^,^[@b11]^--^[@b13]^,^[@b16]^,^[@b17] In fact, in these case series, the proportions of infected men with increased serum AST levels were, respectively, 68.7%, 58.2%, 58.1%, 72.4%, 62.8% and 73.2%, whereas the proportions of infected women were, respectively, 31.3%, 41.8%, 41.9%, 27.6%, 37.2% and 26.8%. It is possible to hypothesize that infected men are more predisposed to develop COVID-19-associated liver dysfunction than infected women, and we suggest that further research is required to better understand this sex-related difference.

Age distribution of COVID-19-related liver dysfunction {#s2-3}
------------------------------------------------------

Of the five case reports, three were in children and two were in adults. The age of children ranged from 3 months to 7 years, whereas the age of adult patients ranged from 35 to 56 years. None of these children had abnormal serum liver enzymes and, therefore, it is possible to hypothesize that older age is associated with a higher likelihood of liver damage/dysfunction. However, further studies are needed to confirm this finding. We look forward to more case reports/case series on COVID-19-related liver damage/dysfunction in different age groups in the future.

Putative mechanisms of COVID-19-related liver dysfunction {#s3}
=========================================================

Angiotensin-converting enzyme *(ACE)2-mediated liver dysfunction* {#s3-1}
-----------------------------------------------------------------

Whether SARS-CoV-2 has direct adverse effects on liver function is currently not known. Some studies have suggested that SARS-CoV-2 predominantly enters alveolar epithelial cells through the human ACE2 receptor.[@b19]^,^[@b20] Therefore, the lung is considered the main target organ of SARS-CoV-2 infection. However, previous studies have found that bile duct epithelial cells may also express ACE2 receptor at a concentration 20 times higher than in hepatocytes and these findings suggest that SARS-CoV-2 infection might also cause bile duct epithelial cell damage.[@b21]^,^[@b22] However, significant increases in circulating levels of serum alkaline phosphatase, bilirubin or gamma-glutamyltransferase (that may reflect bile duct injury) have been rarely reported in COVID-19 patients.[@b9] Liver histopathologic features from COVID-19 patients also did not show any significant damage in hepatocytes or bile duct cells.[@b23] For this reason, it is reasonable to assume that COVID-19-related liver dysfunction is more likely due to secondary liver damage than the use of hepatotoxic therapies or the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, or multiple organ dysfunction.

Drugs {#s3-2}
-----

During the course of the COVID-19 epidemic, many infected patients have been treated with antipyretic agents. Most of these medications contain acetaminophen, which is a drug recognized as being able to cause significant liver damage or induce liver failure.[@b23] It is known that an acute ingestion of \>7.5 to 10 g of acetaminophen in adults or 150 to 200 mg/kg in children is likely to cause hepatotoxicity.[@b24] Although the US Food and Drug Administration Advisory Committee has proposed a decrease in the maximum daily dosage of acetaminophen from 4 to 3 g, and the maximum individual dosage from 1 to 0.65 g, (relegating 500-mg tablets to prescription status), these recommendations have not been implemented worldwide.[@b25] In addition, although there is currently no targeted antiviral treatment for COVID-19, many infected patients have also been treated with some antiviral drugs, such as oseltamivir, abidol or lopinavir, which may have some hepatotoxic effects.

Systemic inflammatory response syndrome {#s3-3}
---------------------------------------

Although many COVID-19 patients were not too unwell, this infection in some patients has resulted in sudden deterioration, ending in multiple organ failure. Most experts believe that the occurrence of multiple organ failure is mainly related to the sudden initiation of an inflammatory "storm" in the critically ill COVID-19 patients.[@b26] The so-called inflammatory "storm", or systemic inflammatory response syndrome, is strongly related to activation of both natural and cellular immunity that is triggered by COVID-19 infection.[@b27] In fact, the virus is able to directly induce multiple proinflammatory signals via toll-like receptors (TLRs) and activation of killer T lymphocytes.[@b28] The activated T lymphocytes then attack the infected body cells, leading to their apoptosis and necrosis, until T lymphocytes are depleted. Damage-related pattern molecules released by dead infected cells can further amplify some inflammatory signals, such as TLRs. At the same time, T-lymphocyte depletion cannot control viral and bacterial infections, thereby activating multiple inflammatory signaling pathways, which lead to macrophage activation and secondary inflammatory reactions. Subsequently, when more inflammatory cytokines are released, more cell damage and necrosis are observed ([Fig. 3](#f03){ref-type="fig"}). Such a vicious cycle is capable of causing multiple injuries, not only to the lungs but also to the liver, heart, and kidneys.

![**Schematic diagram showing the systemic inflammatory response syndrome induced by SARS-CoV2.** After the SARS-CoV-2 infection, pathogenic T cells are rapidly activated, producing granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-6 and other proinflammatory factors. GM-CSF will further activate CD14^+^CD16^+^ inflammatory monocytes, producing a larger amount of IL-6 and other proinflammatory factors, and thereby inducing an inflammatory "storm" that leads to immune damage to other organs, such as the lungs and the liver. Both IL-6 and GM-CSF are two key proinflammatory factors that trigger the inflammatory "storm" in patients with COVID-19.](JCTH-8-018-g003){#f03}

Hypoxia-reperfusion dysfunction {#s3-4}
-------------------------------

Hypoxia and shock induced by COVID-19-related complications (such as respiratory distress syndrome, systemic inflammatory response syndrome, and multiple organ failure) may also cause hepatic ischemia and hypoxia-reperfusion dysfunction. Experimental data showed that hepatic cell death and inflammatory cell infiltration caused by hypoxia can be seen both *in vivo* and *in vitro* models of hepatic ischemia and hypoxia.[@b29] This suggests that oxygen reduction and lipid accumulation in hepatocytes during shock and hypoxic conditions may lead to cell death. The subsequent marked increase in reactive oxygen species and their peroxidation products can act as a second messenger, activating redox-sensitive transcription factors, and further amplifying the release of multiple proinflammatory factors, causing liver damage.[@b30] All the aforementioned findings suggest that pneumonia-associated hypoxia is one of the most important factors causing secondary liver injury in COVID-19 patients.

In summary, the COVID-19-related liver dysfunction may be considered as the result of secondary liver damage caused mainly by several factors, such as the use of potentially hepatotoxic drugs, systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ failure. In addition, critically ill COVID-19 patients with severe liver dysfunction are also more likely to have a poorer prognosis.

Treatment options for COVID-19-related liver dysfunction {#s4}
========================================================

Presently, there is no specific treatment for COVID-19 infection.[@b31] Therefore, the cornerstone of COVID-19 management is patient isolation and supportive medical care where necessary, including pulmonary ventilation and prevention of the underlying inflammatory "storm" as well.[@b32]

From the findings discussed above, however, we believe that it is also reasonable to explore novel treatments for COVID-19 targeting of the ACE2 receptor. The ACE2 cellular receptor is highly expressed in human lung tissues, gastrointestinal tract, liver, vascular endothelial cells, and arterial smooth muscle cells.[@b33] In addition, skin, nasal cavity, and oral mucosa basal cells also express the ACE2 receptor.[@b27] All organs with high expression of the ACE2 receptor may be targeted by SARS-CoV-2 infection.[@b34] Activation of the ACE2/Ang (1-7)/Mas signaling pathway or inhibition of the ACE/Ang II/AT1R pathway could be potential pathways for the treatment of COVID-19. For SARS-CoV-2-infected patients, both ACE-inhibitors and angiotensin-II-receptor antagonists might be used not only for treating high blood pressure but also for reducing systemic inflammatory response and improving patient mortality.[@b35]

Recently, Chen *et al.*[@b36] reported that glycyrrhizic acid derivatives might also have antiviral activity against SARS-CoV-2. Glycyrrhizic acid is one of the first-line drugs for anti-inflammatory protection in liver disease, and it has been used in clinical practice for many years.[@b37] In particular, glycyrrhizic acid is a triterpene glycoside isolated from the root of the licorice plant. ACE2 is a cellular type I membrane protein that is mostly expressed in the lungs, heart, kidneys, and intestine. Full-length ACE2 consists of an N-terminal peptidase domain and a C-terminal collectrin-like domain that ends with a single trans-membrane helix and a ∼40-residue intracellular segment.[@b38] Glycyrrhizin has the potential to bind to ACE2 receptor with an estimated ΔG (kcal/mol) of -9, with the binding sites of ARG-559, GLN-388, ARG-393, and ASP-30.[@b36]

Conclusions {#s5}
===========

Our review shows the following: (1) In highly epidemic areas of COVID-19 infection, such as Wuhan, China, the proportion of infected patients with abnormal liver function test results (mainly elevated serum AST levels) is greater than that observed in regions where a smaller proportion of cases of COVID-19 infection in the population have occurred. (2) The proportion of infected patients with elevated serum transaminase levels is higher in adults than in children and in men than in women, respectively. However, we suggest that further studies are needed to confirm these preliminary observations. In the meantime, we believe that the front-line medical staff should pay attention to liver function tests in patients infected with COVID-19. For those patients with a pre-existing history of liver diseases (especially older patients), special attention should be paid to monitoring hepatic changes caused by COVID-19, whilst carefully identifying the cause of the liver dysfunction.[@b39] We also recommend that front-line medical staff should assess the use of appropriate hepatoprotective therapies, especially in patients with pre-existing liver disease, in order to attenuate the potentially deleterious impact of COVID-19-related liver damage/dysfunction.
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